**Papua New Guinea**

**Tuberculosis profile**

**Population 2018**: 8.6 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>37 (30–45)</td>
<td>432 (352–521)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>2.7 (2.2–3.3)</td>
<td>32 (26–38)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>2 (1.2–2.9)</td>
<td>23 (14–33)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>4.5 (3–6.2)</td>
<td>52 (35–72)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.25 (0.1–0.45)</td>
<td>2.8 (1.2–6.2)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- New cases: 3.4% (1.7–5)
- Previously treated cases: 26% (15–36)

**TB case notifications, 2018**

- Total new and relapse: 27 887
  - % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status: 52%
  - % pulmonary: 56%
  - % bacteriologically confirmed: 30%
  - % children aged 0-14 years: 24%
  - % women: 36%
  - % men: 40%
- Total cases notified: 29 364

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2018: 75% (62–92)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 13% (8–18)

**TB/HIV care in new and relapse TB patients, 2018**

- Number: 1 124
  - on antiretroviral therapy: 909 (81%)

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 400
  - New cases
  - Previously treated cases

**Laboratory-confirmed cases**

- MDR/RR-TB: 433, XDR-TB: 8
- MDR/RR-TB: 401, XDR-TB: 8

**MDR/RR-TB cases tested for resistance to second-line drugs**

- Total Budget (US$ millions)

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 21%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 27% (25–30)

**TB financing, 2019**

- National TB budget (US$ millions): 36
  - Funding source: 52% domestic, 25% international, 24% unfunded

---

*Ranges represent uncertainty intervals
*MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
**MDR/RR-TB cases started on second-line treatment in 2016
*Includes cases with unknown previous TB treatment history
**Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

**Notified cases by age group and sex, 2018**

- **Females**
  - 0-4: 4000
  - 05-14: 2000
  - 15-24: 0
  - 25-34: 0
  - 35-44: 0
  - 45-54: 0
  - 55-64: 0
  - 65+: 0
- **Males**
  - 0-4: 2000
  - 05-14: 0
  - 15-24: 0
  - 25-34: 0
  - 35-44: 0
  - 45-54: 0
  - 55-64: 0
  - 65+: 0

**Treatment success rate (%)**

- New cases
- Previously treated cases
- HIV-positive
- MDR/RR-TB
- XDR-TB

**Total budget (US$ millions)**

- 2015
- 2016
- 2017
- 2018
- 2019

---

*Data are as reported to WHO. Estimates of TB and MDR burden are produced by WHO in consultation with countries.*

*Generated: 2020-03-21*